Epidemiological and clinical characteristics of SARS-CoV-2 infections at a testing site in Berlin, Germany, March and April 2020-a cross-sectional study
- PMID: 32827715
- PMCID: PMC7438270
- DOI: 10.1016/j.cmi.2020.08.017
Epidemiological and clinical characteristics of SARS-CoV-2 infections at a testing site in Berlin, Germany, March and April 2020-a cross-sectional study
Abstract
Objective: In Berlin, the first public severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing site started 1 day after the first case in the city occurred. We describe epidemiological and clinical characteristics and aim at identifying risk factors for SARS-CoV-2 detection during the first 6 weeks of operation.
Methods: Testing followed national recommendations, but was also based on the physician's discretion. We related patient characteristics to SARS-CoV-2 test positivity for exploratory analyses using a cross-sectional, observational study design.
Results: Between 3 March and 13 April 2020, 5179 individuals attended the site (median age 34 years; interquartile range 26-47 years). The median time since disease onset was 4 days (interquartile range 2-7 days). Among 4333 persons tested, 333 (7.7%) were positive. Test positivity increased up to 10.3% (96/929) during the first 3 weeks and then declined, paralleling Germany's lock-down and the course of the epidemic in Berlin. Strict adherence to testing guidelines resulted in 10.4% (262/2530) test positivity, compared with 3.9% (71/1803) among individuals tested for other indications. A nightclub was a transmission hotspot; 27.7% (26/94) of one night's visitors were found positive. Smell and/or taste dysfunction indicated coronavirus disease 2019 (COVID-19) with 85.6% specificity (95% CI 82.1%-88.1%). Four per cent (14/333) of those infected were asymptomatic. Risk factors for detection of SARS-CoV-2 infection were recent contact with a positive case (second week after contact, OR 3.42; 95% CI 2.48-4.71), travel to regions of high pandemic activity (e.g. Austria, OR 4.16; 95% CI 2.48-6.99), recent onset of symptoms (second week, OR 3.61; 95% CI 1.87-6.98) and an impaired sense of smell/taste (4.08; 95% CI 2.36-7.03).
Conclusions: In this young population, early-onset presentation of COVID-19 resembled flu-like symptoms, except for smell and/or taste dysfunction. Risk factors for SARS-CoV-2 detection were return from regions with high incidence and contact with confirmed SARS-CoV-2 cases, particularly when tests were administered within the first 2 weeks after contact and/or onset of symptoms.
Keywords: Asymptomatic; Coronavirus; Coronavirus disease 2019; Olfaction disorders; Screening; Severe acute respiratory syndrome coronavirus 2.
Copyright © 2020. Published by Elsevier Ltd.
Figures


Similar articles
-
Evolution of Altered Sense of Smell or Taste in Patients With Mildly Symptomatic COVID-19.JAMA Otolaryngol Head Neck Surg. 2020 Aug 1;146(8):729-732. doi: 10.1001/jamaoto.2020.1379. JAMA Otolaryngol Head Neck Surg. 2020. PMID: 32614442 Free PMC article.
-
Presence of gustatory and olfactory dysfunction in the time of the COVID-19 pandemic.BMC Infect Dis. 2021 Jun 26;21(1):612. doi: 10.1186/s12879-021-06294-2. BMC Infect Dis. 2021. PMID: 34174816 Free PMC article.
-
Diagnostic Value of Patient-Reported and Clinically Tested Olfactory Dysfunction in a Population Screened for COVID-19.JAMA Otolaryngol Head Neck Surg. 2021 Mar 1;147(3):271-279. doi: 10.1001/jamaoto.2020.5074. JAMA Otolaryngol Head Neck Surg. 2021. PMID: 33410887 Free PMC article.
-
A review of smell and taste dysfunction in COVID-19 patients.Med J Malaysia. 2020 Sep;75(5):574-581. Med J Malaysia. 2020. PMID: 32918429 Review.
-
Universal screening for SARS-CoV-2 infection: a rapid review.Cochrane Database Syst Rev. 2020 Sep 15;9(9):CD013718. doi: 10.1002/14651858.CD013718. Cochrane Database Syst Rev. 2020. PMID: 33502003 Free PMC article.
Cited by
-
Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic.Sci Rep. 2021 Mar 18;11(1):6233. doi: 10.1038/s41598-021-85428-7. Sci Rep. 2021. PMID: 33737535 Free PMC article.
-
Health-related quality of life up to 2 years after SARS-CoV-2 infection: a descriptive cohort study.Epidemiol Infect. 2025 Mar 31;153:e60. doi: 10.1017/S0950268825000366. Epidemiol Infect. 2025. PMID: 40160155 Free PMC article.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Predictors of COVID-19 positivity among patients presenting to screening clinic in a dedicated COVID-19 hospital, in chandigarh, India - A cross-sectional study.J Family Med Prim Care. 2022 Jan;11(1):305-311. doi: 10.4103/jfmpc.jfmpc_1544_21. Epub 2022 Jan 31. J Family Med Prim Care. 2022. PMID: 35309601 Free PMC article.
-
Taste loss as a distinct symptom of COVID-19: a systematic review and meta-analysis.Chem Senses. 2023 Jan 1;48:bjad043. doi: 10.1093/chemse/bjad043. Chem Senses. 2023. PMID: 38100383 Free PMC article.
References
-
- Robert Koch Institute COVID-19-Verdacht: Maßnahmen und Testkriterien - Orientierungshilfe für Ärzte 2020. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Massnahmen_... Available from:
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous